Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals announced positive initial Phase 1b results for ALN-HTT02, now known as brezosiran, aimed at treating Huntington's disease. The data indicates significant huntingtin lowering, supporting the drug's potential efficacy. These findings were shared at the European Huntington's Disease Network conference.

Market Sentiment Analysis

POSITIVE FACTORS

  • Initial Phase 1b data shows positive results.
  • Brezosiran demonstrates deep and durable huntingtin lowering.
  • The study supports further development for Huntington's disease.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Lead asset
ALN-4324
Phase 2 · Type 2 Diabetes Mellitus (T2DM)

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington’s Disease Network (

Frequently Asked Questions

What is brezosiran?

Brezosiran, also known as ALN-HTT02, is an investigational RNAi therapeutic.

What disease is brezosiran targeting?

Brezosiran is being developed for the treatment of Huntington's disease.

What were the results of the Phase 1b trial?

The Phase 1b trial showed positive results with significant huntingtin lowering.

Where were the trial results presented?

The results were presented at the European Huntington's Disease Network conference.

ShareAdd on Google
Tags: ALNY Alnylam brezosiran Huntington's disease RNAi therapeutics clinical trial
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$3308M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 2
Type 2 Diabetes Mellitus (T2DM) →

Catalyst track record

+36%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →